Literature DB >> 8045966

Human kidney 11 beta-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform.

P M Stewart1, B A Murry, J I Mason.   

Abstract

11 beta-Hydroxysteroid dehydrogenase (11 beta HSD) catalyzes the conversion of cortisol to cortisone and plays an important role in the mammalian kidney in regulating cortisol access to the mineralocorticoid receptor. 11 beta HSD-deficient states, such as the syndrome of apparent mineralocorticoid excess (AME), and licorice ingestion result in hypertension in which cortisol acts as a mineralocorticoid. A gene and complementary DNA sequence encoding type I human 11 beta HSD have been described, but this gene is normal in patients with AME. Separate 11 beta HSD isoforms have been described in rat and rabbit kidney, but 11 beta HSD has not been characterized in human kidney. Kinetic analysis of 11 beta HSD activity in human fetal kidney microsomes revealed only a high affinity isoform (apparent Km, 60 nmol/L for cortisol, 13 nmol/L for corticosterone), the activity of which was exclusively nicotinamide adenine dinucleotide (NAD) dependent. No 11-oxo-reductase activity was seen in either renal homogenates or microsomes. 11 beta-Dehydrogenase activity was inhibited by glycyrrhetinic acid (the active ingredient in licorice) in a competitive fashion, with a Ki of 8.7 nmol/L. This 11 beta HSD isoform was clearly distinct from the type I h11 beta HSD enzyme, in that COS-1 cells transfected with type I h11 beta HSD complementary DNA expressed a low affinity (apparent Km, 2.13 mumol/L) isoform, the activity of which was NAD phosphate dependent. 11-Oxo-reductase activity was present in intact transfected cells (apparent Km for cortisone, 0.36 mumol/L), but not in cell lysates. In contrast to the cloned, low affinity, type I h11 beta HSD enzyme, human kidney contains a high affinity NAD-dependent 11 beta HSD isoform. It seems probable that this isoform is responsible for protecting the renal mineralocorticoid receptor from glucocorticoid excess, and a defect in its activity may explain AME.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8045966     DOI: 10.1210/jcem.79.2.8045966

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

Review 1.  Investigation of hypertension and the recognition of monogenic hypertension.

Authors:  D V Milford
Journal:  Arch Dis Child       Date:  1999-11       Impact factor: 3.791

Review 2.  Apparent mineralocorticoid excess syndromes.

Authors:  M Shimojo; P M Stewart
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

3.  Hsd11b2 haploinsufficiency in mice causes salt sensitivity of blood pressure.

Authors:  Matthew A Bailey; Eilidh Craigie; Dawn E W Livingstone; Yuri V Kotelevtsev; Emad A S Al-Dujaili; Christopher J Kenyon; John J Mullins
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

4.  Liquorice-induced apparent mineralocorticoid excess presenting in the emergency department.

Authors:  Stuart Declan Gallacher; Georgios Tsokolas; Ioannis Dimitropoulos
Journal:  Clin Med (Lond)       Date:  2017-02       Impact factor: 2.659

Review 5.  Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: A comprehensive review.

Authors:  Lina Schiffer; Lise Barnard; Elizabeth S Baranowski; Lorna C Gilligan; Angela E Taylor; Wiebke Arlt; Cedric H L Shackleton; Karl-Heinz Storbeck
Journal:  J Steroid Biochem Mol Biol       Date:  2019-07-27       Impact factor: 4.292

6.  Moderate dose cranial radiotherapy causes central adrenal insufficiency in long-term survivors of childhood leukaemia.

Authors:  C Follin; T Wiebe; C Moëll; E M Erfurth
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

7.  Genetic variants of the HSD11B1 gene promoter may be protective against polycystic ovary syndrome.

Authors:  Vince Kornél Grolmusz; Orsolya Dóra Acs; Karolina Feldman-Kovács; Ágnes Szappanos; Balázs Stenczer; Tibor Fekete; György Szendei; Péter Reismann; Károly Rácz; Attila Patócs
Journal:  Mol Biol Rep       Date:  2014-06-27       Impact factor: 2.316

8.  Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.

Authors:  A Li; R Tedde; Z S Krozowski; A Pala; K X Li; C H Shackleton; F Mantero; M Palermo; P M Stewart
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

Review 9.  Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis.

Authors:  Elise P Gomez-Sanchez
Journal:  Steroids       Date:  2014-12       Impact factor: 2.668

10.  A novel NADP(+)-dependent dehydrogenase activity for 7alpha/beta- and 11beta-hydroxysteroids in human liver nuclei: A third 11beta-hydroxysteroid dehydrogenase.

Authors:  B Robinzon; R A Prough
Journal:  Arch Biochem Biophys       Date:  2009-05-03       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.